Penumbra Stockholders Approve $14.5B Merger with Boston Scientific
PEN sits 46% above its 52-week low of $221.26.
Summary
Penumbra Inc. stockholders overwhelmingly approved the merger agreement with Boston Scientific, satisfying a key condition for the $14.5 billion acquisition.
Key Events · M&A and Partnerships · PEN
-
Merger Agreement Approved
Penumbra's stockholders voted to adopt the Agreement and Plan of Merger with Boston Scientific Corporation, with 28,564,786 votes in favor.
-
Key Merger Condition Met
The stockholder approval satisfies a critical condition for the consummation of the $14.5 billion merger.
-
Remaining Conditions Pending
Consummation of the merger is still subject to other closing conditions, including antitrust and foreign investment approvals.
Analysis · PEN · Industrial Applications And Services
This 8-K formally reports the results of the special meeting where Penumbra's stockholders voted to adopt the merger agreement with Boston Scientific Corporation. The overwhelming approval of the merger proposal (over 99% of votes cast) is a critical step towards the consummation of the previously announced $14.5 billion acquisition, removing a significant shareholder-related hurdle. This filing adds specific vote details to the approval previously communicated via a 425 filing today. While this approval satisfies a major condition, the merger remains subject to other closing conditions, including regulatory clearances such as the Hart-Scott-Rodino Antitrust Improvements Act. Investors should monitor progress on these remaining conditions for the finalization of the deal.
At the time of this filing, PEN was trading at $323.86 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.